Viking Therapeutics Inc. (NASDAQ:VKTX) shares are up on Monday, in reaction to data from Novo Nordisk A/S’ (NYSE:NVO) REDEFINE 4 Phase 3 trial of CagriSema (a fixed dose combination of cagrilintide 2.4 mg and semaglutide 2.4 mg) compared to tirzepatide 15 mg.

Novo Nordisk’s stock hit a 52-week low after its REDEFINE 4 trial failed to demonstrate non-inferiority in weight loss compared to Eli Lilly’s tirzepatide, marketed under the Zepbound and Mounjaro brands.

The trial showed a weight loss of 20.2% with CagriSema versus 23.6% with tirzepatide, leading to a significant drop in Novo Nordisk shares.

The REDEFINE 4 trial involved 809 subjects over 84 weeks, and while CagriSema demonstrated a safe profile, the results did not meet expectations.

William Blair analyst Andy Hsieh on Monday wrote that due to the most optimal efficacy/tolerability balance, the GLP-1/GIP dual agonist class will continue to command market leadership in the U.S. against the backdrop of the increasing number of new entrants (oral Wegovy, orforglipron likely in April, and CagriSema by year-end).

REDEFINE 4 results add to the growing body of evidence supporting this view. Beyond Zepbound, Viking’s VK2735, Kailera’s riputapatide, and Roche Holdings AG’s (OTC:RHHBY) CT-388 are in Phase 3 development.

VANQUISH Program For VK2735 Obesity Drug

Viking Therapeutics is making strides with its oral formulation of VK2735, which is expected to enter Phase 3 trials in the third quarter of 2026.

This dual approach—offering both injectable and oral options—positions Viking favorably in a competitive market, as no other dual or triple agonist is currently available in both forms.

Viking’s Stock Shows Mixed Technical Signals

The stock is currently trading above its 20-day simple moving average (SMA), suggesting short-term strength, but below its 50-day and 100-day SMAs, indicating potential challenges in maintaining upward momentum.

Over the past 12 months, shares have gained 11.79%, reflecting a generally positive longer-term trend despite recent volatility.

The RSI is at 40.61, which is considered neutral territory, suggesting the stock is neither overbought nor oversold. Meanwhile, MACD is below its signal line, indicating bearish pressure on the stock.

The combination of neutral RSI and bearish MACD suggests mixed momentum, indicating that traders should watch for potential shifts in market sentiment.

• Key Resistance: $36.00
• Key Support: $29.50

Analyst Consensus & Recent Actions: The stock carries a Buy Rating with an average price target of $92.44. Recent analyst moves include:

• Canaccord Genuity: Buy (Raises Target to $107.00) (Nov. 12, 2025)
• Canaccord Genuity: Initiated with Buy (Target $106.00) (Oct. 29, 2025)
• JP Morgan: Overweight (Lowers Target to $75.00) (Oct. 24, 2025)

VKTX Price Action: Viking Therapeutics shares were up 10.91% at $34.41 at the time of publication on Monday, according to Benzinga Pro data.

Photo by T Schneider via Shutterstock

• No comments yet. Be the first to comment!